Utilizing these established cell lines in appropriate animal models (e.g., xenograft or syngeneic models) is essential to confirm the role of the TGM2/NR3C1-p38 MAPK axis in tumor progression and immune evasion within a physiologically relevant microenvironment, as well as to evaluate its potential as a therapeutic target. This evidence concerns the gene NR3C1 and neoplasm.